Sputnik Light vaccine demonstrates 78.6-83.7% efficacy among the elderly in Argentina

New Delhi: Russian Sputnik Light coronavirus vaccine (the first component of Sputnik V vaccine) has demonstrated 78.6-83.7% efficacy among the elderly, as per data collected by the Ministry of Health of the Buenos Aires province (Argentina).

The data from over 186,000 people aged 60-79, more than 40,000 of whom received a shot of Sputnik Light (first dose of Sputnik V) as part of the mass-scale civil vaccination program, showed that the infection rate between 21st and 40th day from the date of receiving the first dose was only 0.446%.

At the same time, the infection rate among non-vaccinated adult population was 2.74% for a comparable period.

Adjusted data weighted by age, gender and a number of other parameters among groups of vaccinated and non-vaccinated subjects demonstrated comparable efficacy of the Russian vaccine – 78.6%.

Positive official data of vaccination with single-dose Sputnik Light confirms the great efficacy of the vaccine and its potential for being used during the vaccination campaign in Argentina.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF),said: “The publication of independent data in Buenos Aires province confirms high efficacy of the Russian vaccine for senior citizens who are in a high-risk group. An efficacy level of near 83.7% is higher than that of many two-dose vaccines. As the report of the Ministry of Health of the province has demonstrated, vaccination with Sputnik Light (the first component of the Sputnik V vaccine) can significantly reduce the number of infections and hospitalizations. We plan to continue cooperating with colleagues in Argentina for further data on the use of the Russian vaccine.”